Sarepta Therapeutics Inc $ 83.48 0.32 (0.38%)
Volume:
885,427
Avg Vol (1m):
1,954,240
Market Cap $:
6.21 Bil
Enterprise Value $:
5.58 Bil
P/E (TTM):
0.00
P/B:
5.62
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
|
Price: $83.48 | ||
Manual of Stocks™ Web
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 2.29 | ||
| Equity-to-Asset | 0.63 | ||
| Debt-to-Equity | 0.44 | ||
| Debt-to-EBITDA | -0.93 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 4.24 | ||
| Beneish M-Score | -1.86 | ||
| WACC vs ROIC | |||
Profitability | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -162.87 | ||
| Net Margin % | -165.52 | ||
| ROE % | -59.18 | ||
| ROA % | -36.64 | ||
| ROC (Joel Greenblatt) % | -257.54 | ||
| 3-Year Revenue Growth Rate | 433.1 | ||
| 3-Year EBITDA Growth Rate | 1.8 | ||
| 3-Year EPS without NRI Growth Rate | -1.6 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 5.62 | ||
| PS Ratio | 17.01 | ||
| EV-to-EBIT | -10.36 | ||
| EV-to-EBITDA | -10.79 | ||
| EV-to-Revenue | 16.21 | ||
| Current Ratio | 8.81 | ||
| Quick Ratio | 7.84 | ||
| Days Inventory | 940.61 | ||
| Days Sales Outstanding | 59.52 | ||
| Days Payable | 322.44 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 5.68 | ||
| Price-to-Median-PS-Value | 0.65 | ||
| Earnings Yield (Greenblatt) % | -9.65 |